Na K, Park K H, Kim S W, Bae Y H
Center for Biomaterial and Biotechnology, Department of Materials Science and Engineering, Kwangju Institute of Science and Technology, 1 Oryong-Dong, Puk-gu, Kwangju 500-712, South Korea.
J Control Release. 2000 Nov 3;69(2):225-36. doi: 10.1016/s0168-3659(00)00256-x.
Self-assembled hydrogel nanoparticles were synthesized from carboxymethylated (CM)-curdlan, substituted with a sulfonylurea (SU) as a hydrophobic moiety for self-assembly. The degree of SU substitution was 2.4, 5.6, or 7.2 SU groups per hundred anhydroglucose units of curdlan. The physicochemical properties of the self-assembled hydrogel nanoparticles (DS 2.4, DS 5.6, and DS 7.2) in aqueous media were characterized by dynamic light scattering, transmission electron microscopy, and fluorescence spectroscopy. The mean diameter of all samples was less than 300 nm with a unimodal size distribution. The critical aggregation concentrations (CAC) of self-assembled hydrogel nanoparticles in distilled water were 4.2 x 10(-2), 3.1 x 10(-2) and 1.9 x 10(-2) mg/ml for DS 2.4, 5.6 and 7.2, respectively. The loading and release of all-trans retinoic acid (ATRA) was studied. The ATRA loading efficiencies and loading contents of CM-curdlan/SU nanoparticles increased as the degree of SU substitution increased. The ATRA release rate was controlled by the degree of substitution and drug-loading. For specific interaction with a hepatic carcinoma cell line (HepG2), CM-curdlan was additionally conjugated with lactobionic acid (LBA; galactose moiety) (5.5 LBA molecules per hundred glucose units). HepG2 was strongly luminated by ligand-receptor interactions with fluorescence-labeled LBA/CM-curdlan/SU hydrogel nanoparticles. The luminescence was not observed for other control cases. It is concluded that LBA/CM-curdlan/SU hydrogel nanoparticles are a useful drug carrier for the treatment of liver cancer, because of the potential immunological enhancement activities of CM-curdlan in the body, the ligand-receptor mediated specific interactions, and the controlled release of the anti-cancer drug.
自组装水凝胶纳米颗粒由羧甲基化(CM)- 凝胶多糖合成,该多糖用磺酰脲(SU)作为疏水部分进行取代以实现自组装。SU取代度为每100个凝胶多糖脱水葡萄糖单元含2.4、5.6或7.2个SU基团。通过动态光散射、透射电子显微镜和荧光光谱对自组装水凝胶纳米颗粒(取代度2.4、取代度5.6和取代度7.2)在水性介质中的物理化学性质进行了表征。所有样品的平均直径小于300 nm,粒径分布呈单峰。自组装水凝胶纳米颗粒在蒸馏水中的临界聚集浓度(CAC),取代度2.4、5.6和7.2的分别为4.2×10⁻²、3.1×10⁻²和1.9×10⁻²mg/ml。研究了全反式维甲酸(ATRA)的负载和释放情况。随着SU取代度的增加,CM - 凝胶多糖/SU纳米颗粒的ATRA负载效率和负载量增加。ATRA释放速率受取代度和药物负载量控制。为了与肝癌细胞系(HepG2)发生特异性相互作用,CM - 凝胶多糖还与乳糖酸(LBA;半乳糖部分)(每100个葡萄糖单元含5.5个LBA分子)偶联。通过荧光标记的LBA/CM - 凝胶多糖/SU水凝胶纳米颗粒与配体 - 受体相互作用,HepG2被强烈照亮。其他对照情况未观察到发光现象。结论是,LBA/CM - 凝胶多糖/SU水凝胶纳米颗粒是一种用于治疗肝癌的有用药物载体,这是由于CM - 凝胶多糖在体内具有潜在的免疫增强活性、配体 - 受体介导的特异性相互作用以及抗癌药物的控释作用。